28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 May
 
Hey alle   Jeg har nu handlet aktier siden ca. 5 januar. Det startede med at jeg skulle satse ca. 40..
73
20 May
 
Kære Moderator og EI   Det vidner lidt om overvågningen af sitet når en gruppe Nordkoreanern kan få ..
41
19 May
OMXC20CAP
I mit indlæg fra den 20 April : http://www.euroinvestor.dk/debat/post-59413-372203-3659768/rusland-h..
35
24 May
NOVO-B
Ved godt der er en lang Novo tråd lige nedenfor, men synes Elliot fortjener en selvstændig tråd som ..
25
20 May
FING-B
Kære Swiftnick,   Jeg har sagt det tidligere, men jeg gentager gerne budskabet. Sä lyt godt efter! D..
24
22 May
ZEAL
Hvorfor der sker et frasalg har jeg ingen klar ide omkring men der har været en fransk forbindelse s..
20
24 May
ZEAL
Jeg har nærlæst af briefing dokumentet igår aftes, og stiller mig noget undrende overfor nogle af de..
19
19 May
OMXC20CAP
Sorry hap - du er en af dem jeg sjælendt bruger tid på at læse. Dine indlæg er såmen ok, jeg er sikk..
15
25 May
FING-B
Rigtigt mægler - og helt ubegribeligt at derivatmarkedet med dets mange spekulationsformer er tillad..
14
22 May
BAVA
Du får ikke på puklen af mig, jeg er ligeglad.   Men nu siger jeg det igen, selv om jeg er ret sikke..
14

Alliance Trust PLC : Net Asset Value(s)

25/05/2016 13:50:51
ALLIANCE TRUST PLC At the close of business on Tuesday 24 May 2016, the unaudited net asset value per ordinary share of 2.5p, valued on a bid price bas..

Director/PDMR Shareholding

25/05/2016 10:39:04
The Weir Group PLC Notification of interests in shares by PDMR The Weir Group PLC (the Company) received notification on 24 May 2016 from John Heasley..

Alliance Trust PLC : Dividend Declaration

25/05/2016 07:00:44
Dividend Declaration Alliance Trust PLC announces the declaration of a first interim dividend for the year ending 31 December 2016 of 2.825 pence per share p..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sanofi: FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes
2
Sanofi Files Consent Solicitation To Remove and Replace Medivation's Board
3
Camposol announces final results of its Exchange Offer and Settlement Date
4
Prosafe SE: Annual General Meeting held
5
Euler Hermes Group shareholders meeting appoints Marita Kraemer, Ramon Fernandez to the Supervisory Board; Axel Theis succeeds Clement B. Booth as Supervisory Board Chairman

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 May 2016 05:39:13
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20160525.2 - EUROWEB6 - 2016-05-26 06:39:13 - 2016-05-26 05:39:13 - 1000 - Website: OKAY